Literature DB >> 7536386

Iloprost-induced inhibition of proliferation of coronary artery smooth muscle cells is abolished by homologous desensitization.

T Grosser1, D Bönisch, T P Zucker, K Schrör.   

Abstract

In addition to inhibition of platelet function, prostacyclin and its stable analogues are reported to attenuate vascular smooth muscle cell proliferation. However, desensitization of prostacyclin responsiveness is a known phenomenon in platelets. In this study we investigated the time-dependent effects of the prostacyclin-mimetic iloprost and of PGE1, respectively, on PDGF-induced proliferation of cultured coronary artery smooth muscle cells. Proliferation, assessed by [3H]thymidine incorporation was markedly inhibited by coincubation with iloprost (100 nM) and PGE1 (100 nM) for 4 h. In contrast, addition of iloprost (100 nM) for 24 h did not decrease smooth muscle cell proliferation, whereas inhibition by PGE1 or by forskolin was not diminished. These results suggest a homologous desensitization of anti-mitogenic effects of iloprost in coronary artery smooth muscle cells, probably at receptor-level.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536386     DOI: 10.1007/978-3-0348-7346-8_13

Source DB:  PubMed          Journal:  Agents Actions Suppl        ISSN: 0379-0363


  3 in total

1.  Differential regulation of extracellular signal-regulated protein kinases (ERKs) 1 and 2 by cAMP and dissociation of ERK inhibition from anti-mitogenic effects in rabbit vascular smooth muscle cells.

Authors:  R Cospedal; M Lobo; I Zachary
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

Review 2.  Prostacyclin receptor regulation--from transcription to trafficking.

Authors:  C Midgett; J Stitham; K A Martin; J Hwa
Journal:  Curr Mol Med       Date:  2011-10       Impact factor: 2.222

3.  Prostacyclin: an inflammatory paradox.

Authors:  Jeremiah Stitham; Charles Midgett; Kathleen A Martin; John Hwa
Journal:  Front Pharmacol       Date:  2011-05-13       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.